Posted on

In an increasingly hot biotech market, protecting IP is key


John Flavin

More posts by this contributor

2021 should be a banner year for biotech startups that make smart choices early

Kevin O’Connor

Kevin A. O’Connor, Ph.D., is a partner in the Intellectual Property practice group at Neal Gerber Eisenberg.

After a record year for biotech investment in 2020 — during which the industry saw $28.5 billion invested across 1,073 deals — the market for new innovations remains strong. What’s more, these innovations are increasingly coming to market by way of early-stage startups and/or their scientific founders from academia.
In 2018, for instance, U.S. campuses conducted $79 billion worth of sponsored …

Read More